caa a22 4500 475824709 CHVBK 20180406123828.0 cr unu---uuuuu 170329e20001001xx s 000 0 eng 10.1023/A:1018706324908 doi (NATIONALLICENCE)springer-10.1023/A:1018706324908 Clopidogrel and Coronary Stenting: What is the Next Question? [Elektronische Daten] [Scott Moore, Steven Steinhubl] Today, following coronary stenting, clopidogrel has largely replaced ticlopidine as part of combination antiplatelet therapy following coronary stenting primarily due to its better tolerability. While there is no randomized, blinded, efficacy trial of ticlopidine versus clopidogrel, there are ample data from a number of observational studies, randomized non-blinded trials, and a randomized blinded safety trial to prove that clopidogrel is not only safer than ticlopidine, but also at least as efficacious following stenting. With over 10,000 treated patients, pooled data suggest similar rates of stent thrombosis (clopidogrel 0.98% vs. ticlopidine 0.98%) and lower rates of major adverse cardiac events with clopidogrel (clopidogrel 1.63% vs. ticlopidine 4.52%, p<0.001), with a clear advantage for clopidogrel regarding adverse events (clopidogrel 5.91% vs. ticlopidine 9.75%, p<0.001). With clopidogrel's superior safety and at least equivalent efficacy, the question of "which thienopyridine?” post-stenting has been answered. Now the questions "how much?”, "how soon?” and "how long?” must be addressed. The Clopidogrel for the Reduction of Events During Observation (CREDO) trial is a multi-center, double-blind, randomized trial designed to answer these remaining questions. CREDO will evaluate the efficacy and safety of clopidogrel pretreatment versus no pretreatment, and prolonged (1 year), versus short-term (1 month) dual antiplatelet therapy in 2,000 patients undergoing planned or highly probable coronary intervention with a stent. Kluwer Academic Publishers, 2000 clopidogrel nationallicence coronary stent nationallicence Moore Scott Department of Cardiology, Wilford Hall Medical Center, San Antonio, Texas, USA aut Steinhubl Steven Department of Cardiology, Wilford Hall Medical Center, San Antonio, Texas, USA aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 10/2(2000-10-01), 121-126 0929-5305 10:2<121 2000 10 11239 https://doi.org/10.1023/A:1018706324908 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1018706324908 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Moore Scott Department of Cardiology, Wilford Hall Medical Center, San Antonio, Texas, USA aut NATIONALLICENCE 700 1- Steinhubl Steven Department of Cardiology, Wilford Hall Medical Center, San Antonio, Texas, USA aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 10/2(2000-10-01), 121-126 0929-5305 10:2<121 2000 10 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer